Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Glioma/*drug therapy"'
Autor:
Vasilis Golfinopoulos, Roger Stupp, Mohamed Ben Hassel, Jaap C. Reijneveld, Martin J B Taphoorn, A Josephine Drijver, Andreas F. Hottinger, Thierry Gorlia, Elodie Vauleon, Khê Hoang-Xuan, Daniëlle B.P. Eekers, Salvador Villà Freixa, Brigitta G. Baumert, Martin J. van den Bent, Tzahala Tzuk-Shina, Jacolien E.C. Bromberg, A. Lucas, Martin Klein
Publikováno v:
Neuro-Oncology, 23(5), 803-811. Oxford University Press
Neuro-oncology, vol. 23, no. 5, pp. 803-811
Neuro-Oncology
Neuro-Oncology, Oxford University Press (OUP), 2020, 23 (5), pp.803-811. ⟨10.1093/neuonc/noaa252⟩
Neuro-oncology, 23(5), 803-811. Oxford University Press
Neuro Oncol
Klein, M, Drijver, A J, van den Bent, M J, Bromberg, J C, Hoang-Xuan, K, Taphoorn, M J B, Reijneveld, J C, Ben Hassel, M, Vauleon, E, Eekers, D B P, Tzuk-Shina, T, Lucas, A, Freixa, S V, Golfinopoulos, V, Gorlia, T, Hottinger, A F, Stupp, R & Baumert, B G 2021, ' Memory in low-grade glioma patients treated with radiotherapy or temozolomide : a correlative analysis of EORTC study 22033-26033 ', Neuro-Oncology, vol. 23, no. 5, pp. 803-811 . https://doi.org/10.1093/neuonc/noaa252
Dipòsit Digital de la UB
Universidad de Barcelona
Neuro-Oncology, 23(5), 803-811. OXFORD UNIV PRESS INC
Neuro-oncology, vol. 23, no. 5, pp. 803-811
Neuro-Oncology
Neuro-Oncology, Oxford University Press (OUP), 2020, 23 (5), pp.803-811. ⟨10.1093/neuonc/noaa252⟩
Neuro-oncology, 23(5), 803-811. Oxford University Press
Neuro Oncol
Klein, M, Drijver, A J, van den Bent, M J, Bromberg, J C, Hoang-Xuan, K, Taphoorn, M J B, Reijneveld, J C, Ben Hassel, M, Vauleon, E, Eekers, D B P, Tzuk-Shina, T, Lucas, A, Freixa, S V, Golfinopoulos, V, Gorlia, T, Hottinger, A F, Stupp, R & Baumert, B G 2021, ' Memory in low-grade glioma patients treated with radiotherapy or temozolomide : a correlative analysis of EORTC study 22033-26033 ', Neuro-Oncology, vol. 23, no. 5, pp. 803-811 . https://doi.org/10.1093/neuonc/noaa252
Dipòsit Digital de la UB
Universidad de Barcelona
Neuro-Oncology, 23(5), 803-811. OXFORD UNIV PRESS INC
Background EORTC study 22033–26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or temozolomide (TMZ) chemotherapy alone as primary treatment. Considering the potential long
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f70de7d9b3083ced008800d11d981f0
https://cris.maastrichtuniversity.nl/en/publications/ce783292-0ea6-44c0-afe0-df94d7e33785
https://cris.maastrichtuniversity.nl/en/publications/ce783292-0ea6-44c0-afe0-df94d7e33785
Autor:
Jean-Yves Blay, Angelica Fasolo, Palanichamy Ilankumaran, Tae Min Kim, Daniel C Cho, Jeffrey Yachnin, Filip de Vos, Martin J. van den Bent, Eduard Gasal, Albert Lai, Antje Wick, Mario Campone, Damien Pouessel, Myra E. van Linde, Alexander Stein, Jacques De Greve, Warren P. Mason, Jose A. Lopez-Martin, Anas Gazzah, Nikolas von Bubnoff, Vivek Subbiah, Gerald W. Prager, Ralf-Dieter Hofheinz, Patrick Y. Wen, Aislyn Boran, Paul Burgess
Publikováno v:
The Lancet Oncology, 23(1), 53-64. Lancet Publishing Group
Wen, P Y, Stein, A, van den Bent, M, de Greve, J, Wick, A, de Vos, F Y F L, von Bubnoff, N, van Linde, M E, Lai, A, Prager, G W, Campone, M, Fasolo, A, Lopez-Martin, J A, Kim, T M, Mason, W P, Hofheinz, R-D, Blay, J-Y, Cho, D C, Gazzah, A, Pouessel, D, Yachnin, J, Boran, A, Burgess, P, Ilankumaran, P, Gasal, E & Subbiah, V 2022, ' Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR) : a multicentre, open-label, single-arm, phase 2, basket trial ', The Lancet Oncology, vol. 23, no. 1, pp. 53-64 . https://doi.org/10.1016/S1470-2045(21)00578-7
Wen, P Y, Stein, A, van den Bent, M, de Greve, J, Wick, A, de Vos, F Y F L, von Bubnoff, N, van Linde, M E, Lai, A, Prager, G W, Campone, M, Fasolo, A, Lopez-Martin, J A, Kim, T M, Mason, W P, Hofheinz, R-D, Blay, J-Y, Cho, D C, Gazzah, A, Pouessel, D, Yachnin, J, Boran, A, Burgess, P, Ilankumaran, P, Gasal, E & Subbiah, V 2022, ' Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR) : a multicentre, open-label, single-arm, phase 2, basket trial ', The Lancet Oncology, vol. 23, no. 1, pp. 53-64 . https://doi.org/10.1016/S1470-2045(21)00578-7
Background: Effective treatments are needed to improve outcomes for high-grade glioma and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated in adult patients with recurrent or progressive BRAFV600E mutation-positi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fad158cf6a3776974f72e32f6f4611e
https://pure.eur.nl/en/publications/6534e7d9-0966-4ffb-83ef-1054a6161e37
https://pure.eur.nl/en/publications/6534e7d9-0966-4ffb-83ef-1054a6161e37
Autor:
Cristina Barca, Claudia Foray, Sven Hermann, Ulrich Herrlinger, Isabel Remory, Damya Laoui, Michael Schäfers, Oliver M. Grauer, Bastian Zinnhardt, Andreas H. Jacobs
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
Frontiers in Immunology
Immunomodulatory therapies have fueled interest in targeting microglial cells as part of the innate immune response after infection or injury. In this context, the colony-stimulating factor 1 (CSF-1) and its receptor (CSF-1R) have gained attention in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c71155a4e0ea75bbd889f5f0913aac5
https://www.frontiersin.org/articles/10.3389/fimmu.2021.787307/full
https://www.frontiersin.org/articles/10.3389/fimmu.2021.787307/full
Autor:
Christof M. Kramm, Maria Wiese, Dagmar Dilloo, Gerrit H. Gielen, Pablo Hernáiz Driever, Matthias Dürken, Selim Corbacioglu, Michael Karremann, Marion Hoffmann, Wolfram Scheurlen, Andreas Beilken, André O. von Bueren, Andreas E. Kulozik, Nadja Krämer
Publikováno v:
European Journal of Cancer, Vol. 81 (2017) pp. 1-8
Background Temozolomide (TMZ) is widely used in high-grade glioma (HGG). There is a major concern of treatment-induced secondary haematological malignancies (SHMs). Due to the poor overall survival of HGG patients, the true incidence is yet elusive.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce5a64fa25885c70b3633adf75e093dd
https://doi.org/10.1016/j.ejca.2017.04.023
https://doi.org/10.1016/j.ejca.2017.04.023
Autor:
Imen Touihri-Barakati, Belgacem Hanchi, José Luis, Abdennacer Boulila, Olfa Kallech-Ziri, Karim Hosni, Naziha Marrakchi, Khaoula Khwaldia
Publikováno v:
Biomedicine and Pharmacotherapy
Biomedicine and Pharmacotherapy, Elsevier Masson, 2016, 84, pp.1223-1232. ⟨10.1016/j.biopha.2016.10.035⟩
Biomedicine and Pharmacotherapy, Elsevier Masson, 2016, 84, pp.1223-1232. ⟨10.1016/j.biopha.2016.10.035⟩
International audience; In the present study, the effect of Ecbalium elaterium seed oil on adhesion, migration and proliferation of human brain cancer cell line (U87) was determined. Treatment of U87 cell line with the seed oil resulted in strong inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::defb1ac9fb0715fda2d704342ce2bc18
https://doi.org/10.1016/j.biopha.2016.10.035
https://doi.org/10.1016/j.biopha.2016.10.035
Autor:
Johanna A. Joyce, Dongyao Yan, Joanna Kowal, Jason T. Huse, Brian L. West, Alberto J. Schuhmacher, Leila Akkari
Publikováno v:
Oncogene
Oncogene, vol. 36, no. 43, pp. 6049-6058
Oncogene, vol. 36, no. 43, pp. 6049-6058
Glioblastomas represent the most aggressive glioma grade and are associated with a poor patient prognosis. The current standard of care, consisting of surgery, radiation and chemotherapy, only results in a median survival of 14 months, underscoring t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2cedcfb40d6b6d52cc4aebea5872b0e
https://pubmed.ncbi.nlm.nih.gov/28759044
https://pubmed.ncbi.nlm.nih.gov/28759044
Autor:
Touihri-Barakati, Imen, Kallech-Ziri, Olfa, Boulila, Abdennacer, Khwaldia, Khaoula, Marrakchi, Naziha, Hanchi, Belgacem, Hosni, Karim, Luis, José
Publikováno v:
Biomedicine and Pharmacotherapy
Biomedicine and Pharmacotherapy, 2016, 84, pp.1223-1232. ⟨10.1016/j.biopha.2016.10.035⟩
Biomedicine and Pharmacotherapy, Elsevier, 2016, 84, pp.1223-1232. ⟨10.1016/j.biopha.2016.10.035⟩
Biomedicine and Pharmacotherapy, Elsevier Masson, 2016, 84, pp.1223-1232. ⟨10.1016/j.biopha.2016.10.035⟩
Biomedicine and Pharmacotherapy, 2016, 84, pp.1223-1232. ⟨10.1016/j.biopha.2016.10.035⟩
Biomedicine and Pharmacotherapy, Elsevier, 2016, 84, pp.1223-1232. ⟨10.1016/j.biopha.2016.10.035⟩
Biomedicine and Pharmacotherapy, Elsevier Masson, 2016, 84, pp.1223-1232. ⟨10.1016/j.biopha.2016.10.035⟩
International audience; In the present study, the effect of Ecbalium elaterium seed oil on adhesion, migration and proliferation of human brain cancer cell line (U87) was determined. Treatment of U87 cell line with the seed oil resulted in strong inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b2a24ef9fdd79fb4993b858c2f218f07
https://amu.hal.science/hal-01474971/document
https://amu.hal.science/hal-01474971/document
Publikováno v:
Current opinion in neurology, vol. 29, no. 6, pp. 782-788
The management of patients suffering from low-grade gliomas (LGGs) remains a challenge in absence of a definite curative therapy. The median survival is highly variable, from 2 years (high-risk disease) to over 15 years (low risk). The aim of this re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1900::c4d6693861352d9fcee4ba1c71401230
https://serval.unil.ch/resource/serval:BIB_AA45A63A4CB1.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_AA45A63A4CB1.P001/REF.pdf
Autor:
Mohamed Elayeb, Michael Nilges, Houcemeddine Othman, Najet Srairi-Abid, Silke Andrea Wieninger
Publikováno v:
Journal of Biomolecular Structure and Dynamics
Journal of Biomolecular Structure and Dynamics, Taylor & Francis: STM, Behavioural Science and Public Health Titles, 2016, 28, pp.1-15. ⟨10.1080/07391102.2016.1231633⟩
Journal of Biomolecular Structure and Dynamics, 2016, 28, pp.1-15. ⟨10.1080/07391102.2016.1231633⟩
Journal of Biomolecular Structure and Dynamics, Taylor & Francis: STM, Behavioural Science and Public Health Titles, 2016, 28, pp.1-15. ⟨10.1080/07391102.2016.1231633⟩
Journal of Biomolecular Structure and Dynamics, 2016, 28, pp.1-15. ⟨10.1080/07391102.2016.1231633⟩
International audience; Glioblastoma is the deadliest type of brain cancer. Treatment could target the Matrix metalloproteinase-2 (MMP-2), which is known to be involved in the invasion process of glioblastoma cells. But current available inhibitors a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a56d164c27f4884a01b55bc17d36ff95
https://pubmed.ncbi.nlm.nih.gov/27678152
https://pubmed.ncbi.nlm.nih.gov/27678152
Publikováno v:
Annals of Oncology, 19, 209-216. Elsevier Ltd.
Annals of Oncology, Vol. 197, No 7 (2008) pp. vii209-216
Annals of Oncology, Vol. 197, No 7 (2008) pp. vii209-216
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers R. Stupp, A. F. Hottinger, M. J. van den Bent, P.-Y. Dietrich & A. A. Brandes Centre Hospitalier Universitaire Vaudois and University of L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b90b643324c627cb9ef4fd16f9c5cd42
https://doi.org/10.1093/annonc/mdn474
https://doi.org/10.1093/annonc/mdn474